Granules India share price rises 1% as its US unit completes FDA inspection with zero observations

In an exchange filing on December 4, the company informed that it was the second FDA inspection of the facility after the March 2023 audit that resulted in a No Action Indicated (NAI) classification.

Granules India share price

The stock rose as much as 1% to ₹574.40 per unit on the National Stock Exchange. At 12:44 pm, it was up 0.48% to ₹571.

Granules Consumer Health acts as Granules’ front-end division for over the counter (OTC) products in the US, leveragingvGranules India Ltd’s manufacturing efficiencies, regulatory compliance and integrated supply chain.

Dr Krishna Prasad Chigurupati, Chairman and Managing Director of Granules India, said, "Granules Consumer Health plays a critical role in our global operations as a packaging and distribution site. We process controlled substances and over-the-counter (OTC) products across three advanced packaging lines. Achieving zero observations in this inspection reflects our unwavering focus on quality, safety, and regulatory excellence."

On December 1, the company inaugurated two advanced Centres of Excellence -- the Granules Center of Excellence for Particle Engineering (GCEPE) and the Ascelis Center of Excellence for Peptide Development and Characterization (ACEPDC) -- at IIT Hyderabad's Technology Research Park.

In the September quarter of the current fiscal year, the company reported a 34.17% increase in its consolidated revenue from operations to ₹1,296.98 crore. The revenue stood at ₹966.61 crore in the year-ago period.

Its net profit climbed 34.32% to ₹130.6 crore in Q2 FY26, compared to Rs 97.23 crore in the corresponding period of the previous fiscal.